HomeCompareABBV vs NUE

ABBV vs NUE: Dividend Comparison 2026

ABBV yields 3.12% · NUE yields 1.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $67.7K in total portfolio value
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
NUE
NUE
● Live price
1.34%
Share price
$164.75
Annual div
$2.21
5Y div CAGR
36.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.0K
Annual income
$5,036.01
Full NUE calculator →

Portfolio growth — ABBV vs NUE

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVNUE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + NUE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
NUE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
NUE
Annual income on $10K today (after 15% tax)
$114.02/yr
After 10yr DRIP, annual income (after tax)
$4,280.61/yr
At 15% tax rate, ABBV beats the other by $17,586.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + NUE for your $10,000?

ABBV: 50%NUE: 50%
100% NUE50/50100% ABBV
Portfolio after 10yr
$70.8K
Annual income
$15,380.87/yr
Blended yield
21.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
NUE
Analyst Ratings
18
Buy
11
Hold
3
Sell
Consensus: Buy
Price Target
$179.67
+9.1% upside vs current
Range: $176.00 — $183.00
Altman Z
4.4
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
7
NUE buys
0
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVNUE
Forward yield3.12%1.34%
Annual dividend / share$6.65$2.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%36.9%
Portfolio after 10y$104.7K$37.0K
Annual income after 10y$25,725.73$5,036.01
Total dividends collected$63.0K$15.0K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$256.15$179.67

Year-by-year: ABBV vs NUE ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrNUE PortfolioNUE Income/yrGap
1← crossover$11,559$438.51$10,884$183.64+$675.00ABBV
2$13,494$640.86$11,901$255.72+$1.6KABBV
3$15,951$945.97$13,092$357.77+$2.9KABBV
4$19,152$1,413.89$14,512$503.54+$4.6KABBV
5$23,443$2,146.38$16,242$714.13+$7.2KABBV
6$29,391$3,321.96$18,402$1,022.61+$11.0KABBV
7$37,948$5,265.87$21,172$1,482.33+$16.8KABBV
8$50,795$8,596.74$24,836$2,182.08+$26.0KABBV
9$71,034$14,549.41$29,850$3,275.00+$41.2KABBV
10$104,715$25,725.73$36,975$5,036.01+$67.7KABBV

ABBV vs NUE: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

NUEMaterials

Nucor Corporation manufactures and sells steel and steel products. The company's Steel Mills segment produces hot-rolled, cold-rolled, and galvanized sheet steel products; plate steel products; wide-flange beams, beam blanks, and H-piling and sheet piling products; and bar steel products, such as blooms, billets, concrete reinforcing and merchant bars, and special bar quality products. It also engages in the steel trading and rebar distribution businesses. This segment sells its products to steel service centers, fabricators, and manufacturers in the United States, Canada, and Mexico. Its Steel Products segment offers hollow structural section steel tubing products, electrical conduits, steel racking, steel joists and joist girders, steel decks, fabricated concrete reinforcing steel products, cold finished steel products, steel fasteners, metal building systems, insulated metal panels, steel grating and expanded metal products, and wire and wire mesh products primarily for use in nonresidential construction applications. This segment also engages in the piling distribution business. The company's Raw Materials segment produces direct reduced iron (DRI); brokers ferrous and nonferrous metals, pig iron, hot briquetted iron, and DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap metal, as well as engages in the natural gas drilling operations. This segment sells its ferrous scrap to electric arc furnace steel mills and foundries for manufacturing process; and nonferrous scrap metal to aluminum can producers, secondary aluminum smelters, steel mills and other processors, and consumers of various nonferrous metals. It serves agriculture, automotive, construction, energy and transmission, oil and gas, heavy equipment, infrastructure, and transportation industries through its in-house sales force; and internal distribution and trading companies. Nucor Corporation was incorporated in 1958 and is based in Charlotte, North Carolina.

Full NUE Calculator →
📬

Get this ABBV vs NUE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.